CBA Florida, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-09-12: Form 8-K; Period of report 2011-09-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2011-03-23: Form 8-K; Period of report 2011-01-27; Description 8.01 Other Events; Details 8.01.
- 2011-03-22: Form 8-K; Period of report 2011-03-07; Description 8.01 Other Events; Details 8.01.
- 2011-03-21: Form 8-K; Period of report 2011-03-21; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; Details 2.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-09-12 | 8-K | 2011-09-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) (3) On September 12, 2011 Cord Blood America, Inc. a Florida Corporation (the “Company”), entered into Executive Employment Agreements with Matthew L. Schissler, the Company’s Chief Executive Officer, and Joseph R. Vicente, the Company’s Chief Operating Officer and Vice President, which are effective as of August 1, 2011 and shall terminate as of December 31, 2014, unless earlier terminated by the Company or the employees. | cbai_8k.htm |
| 2011-03-23 | 8-K | 2011-01-27 | 8.01 Other Events | 8.01 The Company entered into a non binding Letter of Intent with a large Stem Cell Storage provider located in South America on January 27, 2011, for the acquisition of the South American company, contingent upon among other requirements, the Cord Blood’s completion of due diligence, the execution of a binding definitive agreement, and Cord Blood obtaining a firm commitment from an investment banker to provide the capital required by the Company to consummate the acquisition. | cbai_8k.htm |
| 2011-03-22 | 8-K | 2011-03-07 | 8.01 Other Events | 8.01 The Company entered into a non binding Letter of Intent with a large Cellular Therapeutics and Storage Company located in the United States, for the acquisition of their storage samples rights, assets and business, contingent upon among other requirements, the Company’s completion of due diligence, the execution of a binding definitive agreement, and the Company obtaining a firm commitment from an investment banker to provide the capital required by the Company to consummate the acquisition. | cbai_8k.htm |
| 2011-03-21 | 8-K | 2011-03-21 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | 2.03 On January 12, 2011, the Company issued a $1,050,000 “Convertible Promissory Note” to JMJ Financial (“JMJ”), a private investor (the “2011 Note”). 2.04 Under a previous outstanding Company Convertible Note having similar terms as described in Item 2.03 above and issued to JMJ and funded by JMJ in the amount of approximately $1,750,000(the “Earlier Notes”), the Company was obligated to deliver common shares which could be placed into the Automated System for Deposits and Withdrawals of Securities (known as “DWAC”). | cbai_8k.htm |